A decade of sound science and aggressive deal making has given Sangamo Biosciences a stranglehold on zinc finger technologies. Now, academic labs that helped build Sangamo's empire want in on the action. Are the ingredients ripe for a revolt that could break the company's monopoly? Christopher Thomas Scott investigates.
This is a preview of subscription content, log in via an institution to check access.
References
Kandavelou, K. et al. Nat. Biotechnol. 23, 686–687 (2005).
Hacein-Bey-Abine, S. et al. Science 302, 415–419 (2003).
Urnov, F.D. et al. Nature 435, 646–651 (2005).
Ducor, P. Nat. Biotechnol. 17, 1027–1028 (1999).
Herrera, S. Nat. Biotechnol. 23, 643 (2005).
Broothaerts, W. et al. Nature 433, 629–633 (2005).
Roth, Z. Washington Monthly, p.12–19 (June 2005).
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Scott, C. The zinc finger nuclease monopoly. Nat Biotechnol 23, 915–918 (2005). https://doi.org/10.1038/nbt0805-915
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0805-915
- Springer Nature America, Inc.
This article is cited by
-
Genome editing technologies and their applications in crop improvement
Plant Biotechnology Reports (2018)
-
Ten years of iPSC: clinical potential and advances in vitro hematopoietic differentiation
Cell Biology and Toxicology (2017)
-
Patent Law and Genome Engineering: A Short Guide to a Rapidly Changing Landscape
Molecular Therapy (2016)
-
Genome editing: intellectual property and product development in plant biotechnology
Plant Cell Reports (2016)
-
Gene targeting and editing in crop plants: a new era of precision opportunities
Molecular Breeding (2015)